Cardiologists are closing in , trying to capture the final frontiers. The trans-cutaneous Aortic valve Implantation now has a two year follow up. (NEJM March 2012 Issue) . The results are encouraging .
While two companies are fighting for the supremacy in TAVI , the real threat is for the cardiac surgeons. Currently Edward Sapiens has an edge over Medtronic core valve as it has a provision to redeploy or fine-tune the final geo- position.
Open access article by Martin Leon